Zuellig Pharma and Luye Pharma have signed a Distribution Agreement

Zuellig Pharma receives exclusive rights to market Seroquel and Seroquel XR in Brunei and Malaysia as part of the deal with Luye Pharma Group. Asia’s biggest healthcare services business, Zuellig Pharma, is headquartered in Hong Kong.

In schizophrenia and bipolar disorder, the antipsychotic drugs Seroquel and Seroquel XR are utilized. A number of economies have also authorized Seroquel XR as a treatment for major depression and produced anxiety disorder. Canada’s Network for Mood and Anxiety Treatments (CANMAT) and ISBD’s 2018 recommendations both support quetiapine as a first-line therapy choice.

Luye Pharma considers the Asia Pacific area to be a high-potential developing market. A leader in pharmaceutical distribution, digital marketing, and commercial services in Asia, Zuellig Pharma is headquartered in Singapore. Through a combined effort, the two businesses will be able to effectively grow Seroquel’s business in the Hong Kong Special Administrative Region (SAR), China, in 2020.

“Zuellig Pharma is a great company to work with again. Together with Luye Pharma’s own sales and marketing skills, we think this distribution collaboration will enable patients in these two regions to have easier access to Seroquel products, “Luye Pharma’s APAC Regional Director, Andy Siow, said: (International). To help patients in need, we are also looking forward to collaborating with new corporate partners and combining resources from all sides.According to Luye Pharma’s corporate plan, the company’s business skills have been enhanced globally, and prospects for expansion have been aggressively explored. Luye Pharma’s business presence in the Asia Pacific spans 15 countries and regions, and the firm continues to expand in new regions.